[go: up one dir, main page]

ZA985329B - Compounds - Google Patents

Compounds

Info

Publication number
ZA985329B
ZA985329B ZA985329A ZA985329A ZA985329B ZA 985329 B ZA985329 B ZA 985329B ZA 985329 A ZA985329 A ZA 985329A ZA 985329 A ZA985329 A ZA 985329A ZA 985329 B ZA985329 B ZA 985329B
Authority
ZA
South Africa
Prior art keywords
compounds
Prior art date
Application number
ZA985329A
Other languages
English (en)
Inventor
M Edward Pierson Jr
William F Michne
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Ab filed Critical Astra Ab
Publication of ZA985329B publication Critical patent/ZA985329B/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/20Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D239/22Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
ZA985329A 1997-07-02 1998-06-18 Compounds ZA985329B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9702563A SE9702563D0 (sv) 1997-07-02 1997-07-02 Compounds

Publications (1)

Publication Number Publication Date
ZA985329B true ZA985329B (en) 1999-01-11

Family

ID=20407619

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA985329A ZA985329B (en) 1997-07-02 1998-06-18 Compounds

Country Status (9)

Country Link
US (1) US6057332A (xx)
EP (1) EP0994859A1 (xx)
JP (1) JP2002507988A (xx)
AR (1) AR013152A1 (xx)
AU (1) AU8249898A (xx)
CA (1) CA2294882A1 (xx)
SE (1) SE9702563D0 (xx)
WO (1) WO1999001437A1 (xx)
ZA (1) ZA985329B (xx)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1193259A4 (en) 1999-06-23 2003-01-29 Ajinomoto Kk dihydropyrimidine
WO2003066040A1 (en) 2002-02-05 2003-08-14 Ajinomoto Co.,Inc. Medicinal compositions containing gabapentin or pregabalin and n-type calcium channel antagonist
JP4654035B2 (ja) 2002-11-05 2011-03-16 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 抗菌剤
BR0317313A (pt) * 2002-12-16 2005-11-08 Astrazeneca Uk Ltd Processo para a preparação de um composto, e, composto
WO2005015159A2 (en) * 2003-08-08 2005-02-17 The Regents Of The University Of California. Methods for modulating a drug-related effect or behavior
JP6250561B2 (ja) 2012-02-08 2017-12-20 サノビオン ファーマシューティカルズ インクSunovion Pharmaceuticals Inc. ヘテロアリール化合物およびそれらの使用方法
RU2655914C9 (ru) 2012-08-24 2018-07-24 Саншайн Лейк Фарма Ко., Лтд. Соединения дигидропиримидина и их применение в фармацевтических препаратах
RU2678990C1 (ru) 2013-11-19 2019-02-05 Саншайн Лейк Фарма Ко., Лтд. Соединения дигидропиримидина и их применение в фармацевтических препаратах
AU2014356986B2 (en) 2013-11-27 2018-01-04 Sunshine Lake Pharma Co., Ltd. Processes for preparing dihydropyrimidine derivatives and intermediates thereof
WO2015144093A1 (en) 2014-03-28 2015-10-01 Sunshine Lake Pharma Co., Ltd. Dihydropyrimidine compounds and their application in pharmaceuticals
CN105859708B (zh) 2015-02-07 2020-01-21 广东东阳光药业有限公司 二氢嘧啶衍生物的盐及其在药物中的应用
JP7187437B2 (ja) 2016-07-29 2022-12-12 サノビオン ファーマシューティカルズ インク 化合物および組成物ならびにそれらの使用
EP3490607A4 (en) 2016-07-29 2020-04-08 Sunovion Pharmaceuticals Inc. COMPOUNDS AND COMPOSITIONS, AND USES THEREOF
SG11202000669VA (en) 2017-08-02 2020-02-27 Sunovion Pharmaceuticals Inc Isochroman compounds and uses thereof
KR20210139376A (ko) 2019-03-14 2021-11-22 선오비온 파마슈티컬스 인코포레이티드 이소크로마닐 화합물의 염, 및 이의 결정성 형태, 제조방법, 치료 용도 및 약제학적 조성물

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0202654A3 (en) * 1985-05-20 1987-12-16 E.R. Squibb & Sons, Inc. 5-carboxy-1,4-dihydropyrimidine derivatives
DE69500377T2 (de) * 1994-08-19 1997-10-09 Mitsui Toatsu Chemicals Pyrimidin-Dion-Derivate und diese enthaltende antiarrhythmische Zusammensetzungen

Also Published As

Publication number Publication date
SE9702563D0 (sv) 1997-07-02
AR013152A1 (es) 2000-12-13
CA2294882A1 (en) 1999-01-14
EP0994859A1 (en) 2000-04-26
JP2002507988A (ja) 2002-03-12
WO1999001437A1 (en) 1999-01-14
AU8249898A (en) 1999-01-25
US6057332A (en) 2000-05-02

Similar Documents

Publication Publication Date Title
GB9714102D0 (en) Compounds
GB9715584D0 (en) Compounds
GB9710569D0 (en) Compounds
GB9708694D0 (en) Compounds
GB9708805D0 (en) Compounds
ZA985329B (en) Compounds
GB9709303D0 (en) Compounds
GB9711492D0 (en) Compounds
GB9704522D0 (en) Compounds
GB9702978D0 (en) Compounds
GB9704580D0 (en) Compounds
GB9708936D0 (en) Compounds
GB9708070D0 (en) Compounds
GB9704648D0 (en) Compounds
GB9704581D0 (en) Compounds
GB9702646D0 (en) Compounds
GB9702608D0 (en) Compounds
GB9713818D0 (en) Compounds
GB9702240D0 (en) Compounds
GB9708071D0 (en) Compounds
GB9708072D0 (en) Compounds
GB9707443D0 (en) Compounds
GB9708802D0 (en) Compounds
GB9704551D0 (en) Compounds
GB9706953D0 (en) Compounds